With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a  monthly review of emerging In Vitro  Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced September through October 2014.